The Role of p53 in Nanoparticle-Based Therapy for Cancer

Area of Science:

• Oncology
• Molecular Biology
• Nanomedicine

Background:

• The p53 gene is a critical human tumor suppressor, vital for cell cycle arrest and apoptosis.
• p53 mutations or silencing are prevalent in most cancers, highlighting its importance in cancer development.
• Activated wild-type p53 can induce apoptosis in neighboring cancer cells (bystander effect).

Purpose of the Study:

• To review the current advancements in p53-targeted cancer therapy using nanomedicine.
• To discuss novel strategies for enhancing the efficacy of p53-based nanomedicines.
• To address the limitations of current p53-targeting approaches in p53-inactivated cancers.

Main Methods:

• Systemic delivery of p53-coding DNA or RNA via nanoparticles.
• In vitro and in vivo feasibility studies of p53 nanomedicine.
• Review of existing literature on p53-based cancer therapeutics.

Main Results:

• Nanoparticle-mediated delivery of p53 DNA/RNA is feasible for cancer therapy.
• One p53-based therapy (gendicine) is approved in China.
• Current p53-based therapies exhibit inadequate efficacy in p53-inactivated cancers.

Conclusions:

• p53-targeted therapy is a promising strategy for cancer treatment due to p53's role in apoptosis.
• Overcoming efficacy limitations is crucial for the widespread clinical application of p53 nanomedicine.
• Further research into novel approaches is needed to improve p53-based cancer therapies.